RU2019101632A - Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента - Google Patents
Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента Download PDFInfo
- Publication number
- RU2019101632A RU2019101632A RU2019101632A RU2019101632A RU2019101632A RU 2019101632 A RU2019101632 A RU 2019101632A RU 2019101632 A RU2019101632 A RU 2019101632A RU 2019101632 A RU2019101632 A RU 2019101632A RU 2019101632 A RU2019101632 A RU 2019101632A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- rapamycin
- derivative
- individual
- composition
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims 9
- 229960002930 sirolimus Drugs 0.000 title claims 9
- 102000009027 Albumins Human genes 0.000 title claims 3
- 108010088751 Albumins Proteins 0.000 title claims 3
- 239000002105 nanoparticle Substances 0.000 title claims 3
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010065305 Cancer in remission Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (20)
1. Способ лечения рака у индивидуума, предусматривающий введение этому индивидууму эффективного количества композиции, содержащей наночастицы, которые содержат рапамицин или его производное и белок-носитель.
2. Способ по п. 1, где этот рак является раком ранней стадии, неметастатическим раком, первичным раком, запущенным раком, локально прогрессирующим раком, метастатическим раком, раком в ремиссии, рецидивирующим раком, раком в адъювантном сеттинге, раком в неоадъювантном сеттинге или раком, по существу не поддающимся гормональной терапии.
3. Способ по п. 1, где этот рак является солидной опухолью.
4. Способ по п. 1, где этот рак является плазмацитомой.
5. Способ по п. 1, где этот рак выбран из группы, состоящей из множественной миеломы, почечно-клеточной карциномы, рака предстательной железы, рака легкого, меланомы и рака молочной железы.
6. Способ по п. 1, где этот рак не является раком ободочной кишки.
7. Способ по п. 1, где один или несколько симптомов этого рака являются уменьшенными.
8. Способ по п. 1, где этот рак является задержанным.
9. Способ по п. 1, где количество рапамицина или его производного в эффективном количестве этой композиции находится в диапазоне приблизительно 180 мг – приблизительно 270 мг.
10. Способ по п. 9, где количество рапамицина или его производного в эффективном количестве этой композиции равно приблизительно 216 мг.
11. Способ по п. 1, где рапамицин или его производное вводят парентерально.
12. Способ по п. 1, где рапамицин или его производное вводят внутривенно.
13. Способ по п. 1, где таксан не вводят этому индивидууму.
14. Способ по п. 13, где рапамицин или его производное является единственным фармацевтически активным агентом, применимым для лечения рака, который вводят этому индивидууму.
15. Способ по п. 1, где эта композиция содержит приблизительно более 50% рапамицина или его производного в форме наночастиц.
16. Способ по п. 1, где этот белок-носитель является альбумином.
17. Способ по п. 16, где этот альбумин является сывороточным альбумином человека.
18. Способ по п. 1, где средний диаметр наночастиц в этой композиции равен не более чем приблизительно 200 нм.
19. Способ по п. 1, где массовое отношение белка-носителя к рапамицину или его производному является не большим, чем приблизительно 18:1.
20. Способ по п. 1, где этот индивидуум является человеком.
Applications Claiming Priority (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90567207P | 2007-03-07 | 2007-03-07 | |
| US90573507P | 2007-03-07 | 2007-03-07 | |
| US90566307P | 2007-03-07 | 2007-03-07 | |
| US90573407P | 2007-03-07 | 2007-03-07 | |
| US90566907P | 2007-03-07 | 2007-03-07 | |
| US90566207P | 2007-03-07 | 2007-03-07 | |
| US90578707P | 2007-03-07 | 2007-03-07 | |
| US90575007P | 2007-03-07 | 2007-03-07 | |
| US90576707P | 2007-03-07 | 2007-03-07 | |
| US60/905,750 | 2007-03-07 | ||
| US60/905,672 | 2007-03-07 | ||
| US60/905,735 | 2007-03-07 | ||
| US60/905,767 | 2007-03-07 | ||
| US60/905,669 | 2007-03-07 | ||
| US60/905,662 | 2007-03-07 | ||
| US60/905,734 | 2007-03-07 | ||
| US60/905,663 | 2007-03-07 | ||
| US60/905,787 | 2007-03-07 | ||
| US92324807P | 2007-04-13 | 2007-04-13 | |
| US92345607P | 2007-04-13 | 2007-04-13 | |
| US60/923,456 | 2007-04-13 | ||
| US60/923,248 | 2007-04-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013109422A Division RU2678448C2 (ru) | 2007-03-07 | 2013-03-04 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019101632A true RU2019101632A (ru) | 2020-07-22 |
Family
ID=39562000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009136992/15A RU2483714C2 (ru) | 2007-03-07 | 2008-03-07 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
| RU2013109422A RU2678448C2 (ru) | 2007-03-07 | 2013-03-04 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
| RU2019101632A RU2019101632A (ru) | 2007-03-07 | 2019-01-22 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009136992/15A RU2483714C2 (ru) | 2007-03-07 | 2008-03-07 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
| RU2013109422A RU2678448C2 (ru) | 2007-03-07 | 2013-03-04 | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US8911786B2 (ru) |
| EP (4) | EP3417859A1 (ru) |
| JP (6) | JP2010520289A (ru) |
| KR (5) | KR102154459B1 (ru) |
| CN (1) | CN104814930B (ru) |
| AU (1) | AU2008223334B2 (ru) |
| BR (1) | BRPI0808635B1 (ru) |
| CA (3) | CA3006137C (ru) |
| CY (3) | CY1120548T1 (ru) |
| DK (3) | DK2481402T3 (ru) |
| ES (3) | ES2690174T3 (ru) |
| HR (3) | HRP20181159T1 (ru) |
| HU (3) | HUE038701T2 (ru) |
| IL (2) | IL200755A (ru) |
| LT (3) | LT2131821T (ru) |
| MX (1) | MX2009009537A (ru) |
| NZ (2) | NZ621972A (ru) |
| PL (3) | PL2481402T3 (ru) |
| PT (3) | PT2481402T (ru) |
| RU (3) | RU2483714C2 (ru) |
| SI (3) | SI2481402T1 (ru) |
| UA (1) | UA118645C2 (ru) |
| WO (1) | WO2008109163A1 (ru) |
| ZA (1) | ZA200906342B (ru) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE048521T2 (hu) | 2005-08-31 | 2020-08-28 | Abraxis Bioscience Llc | Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek |
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| JP2010520289A (ja) * | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス， エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| WO2008137148A2 (en) * | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| WO2010005725A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| ES2765240T3 (es) | 2008-06-16 | 2020-06-08 | Pfizer | Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas |
| BRPI0922301A2 (pt) * | 2008-11-28 | 2019-02-26 | Novartis Ag | combinações de inibidor de hsp90 |
| ES2776126T3 (es) | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| AU2010233073B2 (en) * | 2009-04-10 | 2014-07-31 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| CA2783535C (en) | 2009-12-11 | 2017-11-28 | Greg Troiano | Stable formulations for lyophilizing therapeutic particles |
| US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| GB2478556A (en) * | 2010-03-09 | 2011-09-14 | Myrovlytis Technology Ventures Ltd | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
| ES2675212T3 (es) | 2010-03-26 | 2018-07-09 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| WO2012054564A2 (en) * | 2010-10-19 | 2012-04-26 | The Curators Of The University Of Missouri | Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| WO2012149451A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| ES2806268T3 (es) | 2011-04-29 | 2021-02-17 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9731012B2 (en) * | 2012-03-30 | 2017-08-15 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
| EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| CA2881818A1 (en) * | 2012-08-21 | 2014-02-27 | Genesys Research Institute | Compositions and methods for treating or preventing anthracycline induced cardiotoxicity |
| NZ705985A (en) * | 2012-09-17 | 2018-08-31 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| ES2732377T3 (es) | 2012-09-17 | 2019-11-22 | Pfizer | Procedimiento de preparación de nanopartículas terapéuticas |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014107384A1 (en) * | 2013-01-03 | 2014-07-10 | The Board Of Regents Of The University Of Texas System | Rapamycin analogs targeting proteasome function in the treatment of cancer |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2899206C (en) | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| MX370662B (es) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. |
| EP2968370A4 (en) | 2013-03-14 | 2016-09-21 | Univ Maryland | AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF |
| SG11201507234UA (en) * | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| EP2967059A4 (en) * | 2013-03-15 | 2017-03-22 | The Board of Regents of The University of Texas System | Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth |
| KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| WO2014179771A1 (en) * | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| CN111686255A (zh) | 2013-05-03 | 2020-09-22 | 西莱克塔生物科技公司 | 用于诱导免疫耐受的具有特定药效学有效持续期之免疫抑制剂与抗原的递送 |
| EP3033088A4 (en) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| SG11201601218PA (en) | 2013-09-16 | 2016-04-28 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
| WO2015061468A1 (en) * | 2013-10-22 | 2015-04-30 | The University Of North Carolina At Chapel Hill | Polymer nanoparticles containing multiple agents and methods thereof |
| CA2933908C (en) | 2013-12-31 | 2024-01-30 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| HUE043964T2 (hu) | 2014-03-14 | 2019-09-30 | Pfizer | Terápiás szert tartalmazó terápiás nanorészecskék és eljárás ezek elõállítására és alkalmazására |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| CA2957737A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| WO2016172069A1 (en) * | 2015-04-20 | 2016-10-27 | Washington State University | Methods of treating inflammation associated airway diseases and viral infections |
| US9763892B2 (en) | 2015-06-01 | 2017-09-19 | Autotelic Llc | Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods |
| MX2017016519A (es) * | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
| BR112017028132A2 (pt) * | 2015-06-29 | 2018-08-28 | Abraxis Bioscience Llc | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula |
| CN108024999A (zh) * | 2015-06-29 | 2018-05-11 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| MX2017016492A (es) * | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor). |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| CA2995384A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | INTERFERON CANCER TREATMENT METHODS |
| EP3411032B1 (en) | 2016-02-04 | 2020-09-30 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| CA3013783A1 (en) * | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapaglutins, novel inhibitors of glut and use thereof |
| CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| JP2019511903A (ja) | 2016-02-19 | 2019-05-09 | ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ | 免疫原性調節の方法 |
| JP2019510085A (ja) * | 2016-03-08 | 2019-04-11 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療のためのナノ粒子ならびに方法および化合物 |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| JP7525999B2 (ja) | 2016-09-01 | 2024-07-31 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| KR20190053203A (ko) | 2016-09-01 | 2019-05-17 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Ｔ－세포 암을 표적화하는 방법 및 조성물 |
| KR20230011473A (ko) | 2016-09-06 | 2023-01-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Ｐｄ－ｌ１ 발현 암의 치료 방법 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| KR20230010817A (ko) | 2016-09-06 | 2023-01-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법 |
| EP3518923A4 (en) * | 2016-09-28 | 2020-06-17 | Abraxis BioScience, LLC | METHODS OF TREATING MITOCHONDRIAL AND METABOLIC DISORDERS |
| EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Anhydrous compositions of MTOR inhibitors and method of use |
| ES2944576T3 (es) * | 2017-01-06 | 2023-06-22 | Santen Pharmaceutical Co Ltd | Administración intratumoral de sirólimus para el tratamiento del cáncer de próstata |
| EP3592389A1 (en) | 2017-03-11 | 2020-01-15 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US10806801B2 (en) * | 2017-06-07 | 2020-10-20 | National Cheng Kung University | Pharmaceutical composition and methods for using the same |
| WO2019073371A1 (en) | 2017-10-11 | 2019-04-18 | Wockhardt Limited | PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES |
| BR112020012060A2 (pt) * | 2017-12-19 | 2020-11-24 | Abraxis Bioscience, Llc | métodos de tratamento de câncer de cólon usando uma terapia de combinação com nanopartícula de inibidor de mtor |
| AU2018389243A1 (en) * | 2017-12-21 | 2020-08-06 | The Angiogenesis Foundation | Compositions and methods for treating neoplasia |
| WO2019162048A1 (en) | 2018-02-23 | 2019-08-29 | Biotronik Ag | Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures |
| SG11202009145PA (en) * | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| SG11202011462SA (en) | 2018-05-22 | 2020-12-30 | Abraxis Bioscience Llc | Methods and compositions for treating pulmonary hypertension |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| WO2020191053A1 (en) * | 2019-03-19 | 2020-09-24 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases |
| WO2021011753A1 (en) * | 2019-07-16 | 2021-01-21 | The Regents Of The University Of Michigan | Composite drug particles and uses thereof |
| MX2022004989A (es) * | 2019-10-28 | 2022-07-21 | Abraxis Bioscience Llc | Composiciones farmaceuticas de albumina y rapamicina. |
| US20230000844A1 (en) * | 2019-11-11 | 2023-01-05 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| KR102641217B1 (ko) * | 2019-12-24 | 2024-02-29 | (주)아이엠지티 | 항암제가 코팅된 알부민 나노입자 및 이의 제조방법 |
| KR102517033B1 (ko) | 2020-07-15 | 2023-04-03 | 성균관대학교산학협력단 | 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| AU2021397776A1 (en) * | 2020-12-10 | 2023-06-22 | Children's Hospital Medical Center | Enhanced nanoparticle delivery systems |
| WO2022226052A1 (en) * | 2021-04-20 | 2022-10-27 | The Regents Of The University Of Michigan | Pi3k inhibitors, nanoformulations, and uses thereof |
| KR20240044603A (ko) | 2022-09-28 | 2024-04-05 | 충남대학교산학협력단 | 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| CN1245156C (zh) | 1993-02-22 | 2006-03-15 | 美国生物科学有限公司 | 用于体内传送生物制品的方法及用于该方法的组合物 |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20070122465A1 (en) | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| EP1683517A1 (en) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN100462066C (zh) | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| WO2000064437A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| CA2371912C (en) | 1999-05-21 | 2010-02-16 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| CN1296043C (zh) * | 2001-02-19 | 2007-01-24 | 诺瓦提斯公司 | 式i的雷帕霉素化合物在制备用于治疗实体瘤的药物组合物中的用途 |
| DE60228699D1 (de) | 2001-04-06 | 2008-10-16 | Wyeth Corp | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil |
| KR100875611B1 (ko) * | 2001-06-01 | 2008-12-24 | 와이어쓰 | ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| JP4212921B2 (ja) * | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
| AU2003226349B2 (en) | 2002-04-11 | 2008-01-31 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| KR20190034694A (ko) * | 2002-12-09 | 2019-04-02 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| WO2004060283A2 (en) | 2002-12-16 | 2004-07-22 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US20050038498A1 (en) | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
| US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| JP4689666B2 (ja) * | 2004-05-14 | 2011-05-25 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | アルブミン結合蛋白質を標的として用いる治療法 |
| RU2006144809A (ru) | 2004-05-17 | 2008-06-27 | Новартис АГ (CH) | Комбинация органических соединений |
| EP2452670A1 (en) * | 2004-10-01 | 2012-05-16 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| WO2006053754A1 (en) | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1848352A4 (en) * | 2005-02-18 | 2011-07-20 | M S Abdou | DEVICES AND METHODS FOR DYNAMICALLY FIXING A SKELETAL STRUCTURE |
| WO2006089207A2 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| KR20070121758A (ko) | 2005-03-17 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 면역 억제 화합물의 주사가능한 조성물 |
| DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
| US7514549B2 (en) * | 2005-04-16 | 2009-04-07 | Michigan State University | Tumor inhibition by modulating sprouty expression or activity |
| WO2006124739A1 (en) | 2005-05-16 | 2006-11-23 | Novartis Ag | The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| HUE048521T2 (hu) | 2005-08-31 | 2020-08-28 | Abraxis Bioscience Llc | Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek |
| US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
| CN101568332A (zh) | 2006-08-31 | 2009-10-28 | 阿布拉科斯生物科学公司 | 抑制血管生成及治疗血管生成相关疾病的方法 |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| JP2010520289A (ja) | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス， エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| WO2008150532A1 (en) | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| ES2668837T3 (es) | 2008-12-11 | 2018-05-22 | Abraxis Bioscience, Llc | Terapia de combinación que incluye un taxano y un agente terapéutico adicional |
| CA2755121A1 (en) | 2009-03-13 | 2010-09-16 | Neil P. Desai | Combination therapy with thiocolchicine derivatives |
| US20130195983A1 (en) | 2009-04-10 | 2013-08-01 | Neil P. Desai | Nanoparticle formulations and uses thereof |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| US20130045240A1 (en) | 2009-08-25 | 2013-02-21 | Abraxis Bioscience, Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| US9775819B2 (en) | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| ES2675212T3 (es) | 2010-03-26 | 2018-07-09 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| US20130266659A1 (en) | 2010-06-02 | 2013-10-10 | Neil P. Desai | Methods of treating bladder cancer |
| MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| SG11201507234UA (en) * | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
-
2008
- 2008-03-07 JP JP2009552757A patent/JP2010520289A/ja not_active Withdrawn
- 2008-03-07 DK DK12152455.7T patent/DK2481402T3/en active
- 2008-03-07 ES ES12152455.7T patent/ES2690174T3/es active Active
- 2008-03-07 PL PL12152455T patent/PL2481402T3/pl unknown
- 2008-03-07 LT LTEP08726605.2T patent/LT2131821T/lt unknown
- 2008-03-07 KR KR1020197033753A patent/KR102154459B1/ko active IP Right Grant
- 2008-03-07 CN CN201510163181.4A patent/CN104814930B/zh active Active
- 2008-03-07 CA CA3006137A patent/CA3006137C/en active Active
- 2008-03-07 PL PL12152463T patent/PL2481409T3/pl unknown
- 2008-03-07 NZ NZ621972A patent/NZ621972A/en unknown
- 2008-03-07 SI SI200831985T patent/SI2481402T1/sl unknown
- 2008-03-07 DK DK12152463.1T patent/DK2481409T3/en active
- 2008-03-07 SI SI200831980T patent/SI2131821T1/sl unknown
- 2008-03-07 KR KR1020147033327A patent/KR20150002886A/ko not_active Application Discontinuation
- 2008-03-07 ES ES08726605.2T patent/ES2686150T3/es active Active
- 2008-03-07 LT LTEP12152455.7T patent/LT2481402T/lt unknown
- 2008-03-07 MX MX2009009537A patent/MX2009009537A/es active IP Right Grant
- 2008-03-07 RU RU2009136992/15A patent/RU2483714C2/ru active
- 2008-03-07 PL PL08726605T patent/PL2131821T3/pl unknown
- 2008-03-07 PT PT12152455T patent/PT2481402T/pt unknown
- 2008-03-07 WO PCT/US2008/003096 patent/WO2008109163A1/en active Application Filing
- 2008-03-07 KR KR1020197001911A patent/KR102047634B1/ko active IP Right Grant
- 2008-03-07 ES ES12152463.1T patent/ES2690175T3/es active Active
- 2008-03-07 DK DK08726605.2T patent/DK2131821T3/en active
- 2008-03-07 PT PT08726605T patent/PT2131821T/pt unknown
- 2008-03-07 LT LTEP12152463.1T patent/LT2481409T/lt unknown
- 2008-03-07 US US12/530,188 patent/US8911786B2/en active Active
- 2008-03-07 CA CA2680207A patent/CA2680207C/en active Active
- 2008-03-07 KR KR1020097020819A patent/KR20090118999A/ko not_active Application Discontinuation
- 2008-03-07 HU HUE08726605A patent/HUE038701T2/hu unknown
- 2008-03-07 EP EP18167003.5A patent/EP3417859A1/en active Pending
- 2008-03-07 HU HUE12152463A patent/HUE039497T2/hu unknown
- 2008-03-07 NZ NZ711695A patent/NZ711695A/en unknown
- 2008-03-07 PT PT12152463T patent/PT2481409T/pt unknown
- 2008-03-07 EP EP08726605.2A patent/EP2131821B1/en active Active
- 2008-03-07 SI SI200831982T patent/SI2481409T1/sl unknown
- 2008-03-07 BR BRPI0808635-4A patent/BRPI0808635B1/pt active IP Right Grant
- 2008-03-07 AU AU2008223334A patent/AU2008223334B2/en active Active
- 2008-03-07 CA CA3201293A patent/CA3201293A1/en active Pending
- 2008-03-07 HU HUE12152455A patent/HUE039643T2/hu unknown
- 2008-03-07 UA UAA201213559A patent/UA118645C2/uk unknown
- 2008-03-07 EP EP12152463.1A patent/EP2481409B1/en active Active
- 2008-03-07 EP EP12152455.7A patent/EP2481402B1/en active Active
- 2008-03-07 KR KR1020177002049A patent/KR101943230B1/ko active IP Right Grant
-
2009
- 2009-09-06 IL IL200755A patent/IL200755A/en active IP Right Grant
- 2009-09-11 ZA ZA2009/06342A patent/ZA200906342B/en unknown
-
2013
- 2013-02-27 US US13/779,621 patent/US20130280336A1/en not_active Abandoned
- 2013-03-04 RU RU2013109422A patent/RU2678448C2/ru active
- 2013-10-28 JP JP2013223132A patent/JP6348698B2/ja active Active
-
2014
- 2014-10-28 US US14/526,358 patent/US20150050356A1/en not_active Abandoned
-
2015
- 2015-10-14 JP JP2015202611A patent/JP2016011309A/ja not_active Withdrawn
-
2017
- 2017-02-05 IL IL250445A patent/IL250445A0/en unknown
- 2017-05-10 JP JP2017093894A patent/JP6544812B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127659A patent/JP2018150381A/ja active Pending
- 2018-07-23 HR HRP20181159TT patent/HRP20181159T1/hr unknown
- 2018-07-27 HR HRP20181198TT patent/HRP20181198T1/hr unknown
- 2018-07-30 HR HRP20181217TT patent/HRP20181217T1/hr unknown
- 2018-08-08 CY CY20181100825T patent/CY1120548T1/el unknown
- 2018-08-08 CY CY20181100824T patent/CY1120547T1/el unknown
- 2018-08-08 CY CY20181100826T patent/CY1120555T1/el unknown
- 2018-09-24 US US16/140,339 patent/US20190022020A1/en not_active Abandoned
-
2019
- 2019-01-22 RU RU2019101632A patent/RU2019101632A/ru not_active Application Discontinuation
- 2019-10-09 JP JP2019185794A patent/JP2020002177A/ja active Pending
-
2021
- 2021-02-24 US US17/184,506 patent/US20210322335A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,775 patent/US20240065984A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
| Kodera et al. | A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study) | |
| Yamaguchi et al. | Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer | |
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| Hass et al. | Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases | |
| JP2006503919A5 (ru) | ||
| JP2019521087A5 (ru) | ||
| JP2010520289A5 (ru) | ||
| JP2009513662A5 (ru) | ||
| WO2004071436A3 (en) | The use of gcc ligands | |
| JP2021500349A5 (ru) | ||
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| Li et al. | DDTC-Cu (I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis | |
| Sekine et al. | Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer | |
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer | |
| JP7372253B2 (ja) | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ | |
| Osugi et al. | Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination | |
| RU2007104053A (ru) | Лечение рака | |
| Mori et al. | Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results | |
| Takekida et al. | Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer | |
| Cao et al. | Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer | |
| Okuma et al. | S-1 is an active anticancer agent for advanced thymic carcinoma | |
| Keller et al. | Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas | |
| CN114401747A (zh) | 抗核仁素剂-peg缀合的纳米颗粒 | |
| Kawabata et al. | Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20220124 |